From the bench to an evolving controversy

Journal of Supportive Oncology

Volumn 3, Issue 1, 2005, Pages 26-27

  Paice, Judith A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; ROFECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; BONE CANCER; CANCER PAIN; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; NEUROBIOLOGY; NEUROPATHY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; TAIL FLICK TEST; TREATMENT PLANNING; VISCERAL PAIN; ANIMAL; BONE TUMOR; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HOSPITALIZATION; INTRACTABLE PAIN; METASTASIS; NOTE; PAIN ASSESSMENT; PEER REVIEW; RAT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE NEOPLASMS; CHRONIC DISEASE; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PAIN MEASUREMENT; PAIN, INTRACTABLE; PEER REVIEW; RATS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 15544383386     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Polomano RC, Mannes AJ, Clark US, Bennett G.J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug paclitaxel. Pain 2001;94:293-304.
2. Gebhart GF. J.J. Bonica Lecture - 2000: Physiology, pathophysiology, and pharmacology of visceral pain. Reg Anesth Pain Med 2000;25:632-638.
3. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
4. Topol EJ. Failing the public health - rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709.
5. Couzin J. Drug safety: withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 2004;306:384-385.
6. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-2073.
7. NIH News. NIH halts use of COX-2 inhibitor in large cancer prevention trial. Available at: http://www.nih.gov/news/pr/dec2004/od-17.htm. Accessed December 21, 2004.
8. CNN News. Concerns raised about naproxen. Available at: http://www.cnn.com/2004/HEALTH/12/20/study.halted.ap/index.html. Accessed December 21, 2004.